Roche Diagnostics in Indianapolis is preparing to launch the first Alzheimer’s blood-based test in the world designed for the primary care setting.
“Prior to this test, the biomarker testing of Alzheimer’s disease has been only limited to specialty care, which is mainly neurology,” Roche Diagnostics Senior Vice President of Medical and Scientific Affairs Cagri Senyucel said. “I believe this is a milestone in the assessment of Alzheimer’s disease.”
The Elecsys pTau 181 test was developed in collaboration with Indianapolis-based Eli Lilly and Co. and does not diagnose Alzheimer’s. Instead, Roche’s test looks for the same protein in the blood that doctors have traditionally spotted in brain images as the key indicator of Alzheimer’s. It is used for patients ages 55 and older.
“If a patient runs this test and [they] have a negative result, this patient is unlikely to have Alzheimer’s disease. If a patient has a positive result, that prompts a referral to neurology,” Senyucel said.
Conventional methods require a PET scan, which is much more expensive—or a more invasive spinal fluid test. Both methods require a neurologist.
Senyucel says Roche scientists around the world worked on developing the test. The equipment that runs the test is already installed in 4,500 labs across the country, and Roche says most labs can deliver a test result within a day.
“This is something [that] enables primary care physicians to assess the Alzheimer’s disease much earlier and then refer the patients to the right physicians. Alzheimer’s is one of the largest unmet medical needs worldwide right now,” he said. “I’m very proud of the Roche ongoing effort in the past two decades on Alzheimer research, and we are continuing to do so.”
According to the Alzheimer’s Association, over 7 million Americans are living with the disease. By 2050, the number is projected to be around 13 million.
Roche says patients will be able to start taking this test early next year.
The Elecsys pTau 181 test isn’t the only Roche test making headlines. In September, the company received U.S. regulatory clearance for a less-complex vitamin D test in the United States.
The company said the approval opens the door to more efficient diagnostics using its mass spectrometry system.
